Dataset from A Phase III Study to Demonstrate the Antiviral Activity and Safety of Dolutegravir in HIV-1 Infected Adult Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00009168
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this trial is to assess the antiviral activity and safety of a dolutegravir
(DTG) containing regimen in HIV-1 infected, antiretroviral therapy (ART)-experienced adults
with current or historical failure on an integrase inhibitor (INI) containing regimen. The
study will assess DTG 50mg twice daily administered initially with the current failing ART
regimen but then with an optimised background ART regimen (OBR) after Day 7. The first
analyses will be conducted after the last subject enrolled has completed 24 weeks. Subjects
may remain on study after Week 24.
创建时间：
2024-11-27
